Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC

Fumio Imamura; Takako Inoue; Kei Kunimasa; Aki Kubota; Hanako Kuhara; Motohiro Tamiya; Kazumi Nishino; Madoka Kimura; Kika Kuno; Hayato Kawachi; Toru Kumagai

doi:10.2217/lmt-2020-0005

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC

Lung Cancer Manag. 2020 Mar 19;9(2):LMT29. doi: 10.2217/lmt-2020-0005.

Authors

Affiliations

¹ Department of Thoracic Oncology, Osaka International Cancer Institute 3-1-69 Otemae, Chio-ku, Osaka 541-8567, Japan.
² Department of Biomedical Statistics & Bioinformatics, Kyoto University Graduate School of Medicine 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Abstract

Aim: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC.

Materials & methods: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for T790M-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.

Results: Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.

Conclusion: Switch use of osimertinib seemed to produce improved efficacy for patients with activating EGFR mutations, because of the lack of patient selection via T790M.

Keywords: EGFR mutation; EGFR-TKI; NSCLC; osimertinib; switch; time to failure of strategy.